<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01116271</url>
  </required_header>
  <id_info>
    <org_study_id>D9010C00009</org_study_id>
    <secondary_id>AGICC 09CRC02</secondary_id>
    <nct_id>NCT01116271</nct_id>
  </id_info>
  <brief_title>Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec</brief_title>
  <official_title>A Dose Finding and Phase II Study of Selumetinib (AZD6244) (Hyd-Sulfate) in Combination With Irinotecan, in 2nd Line Patients With K-ras or B-raf Mutation Positive Advanced or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with Selumetinib (AZD6244)
      (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or
      B-raf mutation will prevent tumor progression and prolong progression free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Dose Finding and Phase II Study of Selumetinib (AZD6244) (Hyd-Sulfate) in Combination with
      Irinotecan, in 2nd Line Patients with K-ras or B-raf Mutation Positive Advanced or Metastatic
      Colorectal Cancer
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Finding will be calculated based upon toxicity screening and dose modification guidelines within protocol.</measure>
    <time_frame>AEs will be assessed at each cycle visit, discontinuation treatment visit, and 30 days post last day of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate will be assessed by the RECIST guideline documented in the European Journal of Cancer, 2009.</measure>
    <time_frame>Tumor evaluation via RECIST guidelines will be done on screening visit, day 22 of every other cycle, and treatment discontinuation visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of combination of Selumetinib (AZD6244) with irinotecan by SAE and AE documentation</measure>
    <time_frame>AEs will be assesed at the screening visit, each cycle visit, treatment discontinuation date, and 30 days post last day of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Selumetinib (AZD6244), N-desmethyl Selumetinib(AZD6244) and selumetinib (AZD6244) amide in combination with irinotecan</measure>
    <time_frame>PK sample draws will take place on Day 1 and 15 of first cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) for patients with K-ras or B-raf mutations treated with combination of irinotecan and Selumetinib (AZD6244)</measure>
    <time_frame>PFS will be determined via the RECIST guidelines on tumor measurement done on day 22 of every other cycle and on the treatment discontinuation visit</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selumetinib (AZD6244) in combination with irinotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6244</intervention_name>
    <description>50 or 75mg, capsules, PO, BID, 28 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Selumetinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>180mg/m2, IV, Day 1&amp; 15 of each cycle</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Camptosar; Campto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Histological or cytological confirmation of advanced or metastatic colorectal cancer with
        available tissue and tumor sample confirmed as K-ras or B-raf mutation positive. Current
        failure of 1st line anti-cancer therapy with an oxaliplatin and bevacizumab based regimen
        or patients relapsing within 12 months of completing adjuvant FOLFOX .

        Exclusion Criteria:

        - Treatment within 14 days prior to first study treatment with conventional therapy or
        treatment within 28 days prior to first study treatment with an investigational drug Prior
        treatment with a MEK or B-raf inhibitor or any irinotecan-containing regimen Prior
        treatment with a MEK or B-raf inhibitor or any irinotecan-containing regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Hochster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Leichman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Desert Regional Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reserach Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Washington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2010</study_first_submitted>
  <study_first_submitted_qc>May 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2010</study_first_posted>
  <last_update_submitted>January 11, 2013</last_update_submitted>
  <last_update_submitted_qc>January 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal</keyword>
  <keyword>second line therapy</keyword>
  <keyword>K-ras or B-raf mutations</keyword>
  <keyword>response rate</keyword>
  <keyword>Progression Free Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

